In a bipartisan spending agreement that was largely negotiated behind closed doors, Congress included a policy change with ...
Kansas legislators, Republican and Democrat, are frustrated bills to help control prescription drug prices are blocked by GOP ...
The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.
On March 17, 2026, the Ninth Circuit issued a unanimous decision in United States ex rel. Adventist Health Sys. of W. v. AbbVie Inc. allowing a ...
Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under ...
The closer we get to 2028, the more likely it is that the U.S. may settle for short-term solutions that do not meaningfully ...
The Well News on MSNOpinion
340B has gone off the rails
A federal court recently blocked the Trump administration from moving forward with a proposed pilot program that could have ...
If New York legislators have questions about the efficacy of the 340B Drug Pricing Program, they should look closely at a ...
Dartmouth hospital CFO details 340B designation risk and strategic partnership to safeguard federal program participation at ...
The 340B program presents covered entities with very important financial support to assist with the extension of care to the most vulnerable populations. However, the program is under scrutiny from ...
The past year has seen a great deal of controversy surrounding the 340B Drug Pricing Program, in which drug manufacturers make prescription drugs available to safety net healthcare providers at deeply ...
The original goal of the 340B drug discount program was to allow qualified providers to “stretch federal resources as far as possible reaching more eligible patients and providing more comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results